Federated Hermes Inc. Sells 295,600 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Federated Hermes Inc. trimmed its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 5.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,767,926 shares of the company's stock after selling 295,600 shares during the period. Federated Hermes Inc. owned about 5.44% of IDEAYA Biosciences worth $78,099,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Mariner LLC grew its holdings in IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after acquiring an additional 869 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in IDEAYA Biosciences by 6.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company's stock worth $349,000 after acquiring an additional 1,214 shares during the period. NEOS Investment Management LLC grew its holdings in IDEAYA Biosciences by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 16,066 shares of the company's stock worth $413,000 after acquiring an additional 1,577 shares during the period. CWM LLC grew its holdings in IDEAYA Biosciences by 325.7% during the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after acquiring an additional 1,814 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in IDEAYA Biosciences during the 4th quarter worth about $47,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA traded down $0.08 during midday trading on Friday, reaching $24.27. The company's stock had a trading volume of 860,814 shares, compared to its average volume of 982,643. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $41.08. The firm has a 50 day moving average price of $22.07 and a 200-day moving average price of $20.35. The stock has a market capitalization of $2.13 billion, a P/E ratio of -6.76 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the firm posted ($0.53) earnings per share. On average, equities analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Ratings Changes

IDYA has been the subject of a number of recent analyst reports. Wells Fargo & Company began coverage on IDEAYA Biosciences in a report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and cut their price objective for the stock from $57.00 to $30.00 in a research report on Wednesday, July 9th. TD Cowen began coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a "buy" rating on the stock. The Goldman Sachs Group raised shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective on the stock in a research report on Thursday, July 10th. Finally, JPMorgan Chase & Co. increased their price objective on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a research report on Monday, July 28th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, IDEAYA Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $48.09.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.